Harmony Biosciences, LLC, is a private biopharmaceutical company headquartered in Plymouth Meeting, PA. The company was established in October 2017, with a vision to provide novel treatment options for people living with rare diseases, with an emphasis on central nervous system disorders, starting with patients living with narcolepsy.
In October 2017, the company acquired exclusive U.S. rights to develop, register and market the drug pitolisant from French company, Bioprojet SCR (Bioprojet) to address unmet needs for patients with sleep and other central nervous system disorders. Harmony secured $270 million in equity financing from highly experienced equity investors including: Bioprojet; Fidelity Management and Research Company; HBM Healthcare Investments; Nan Fung LIfe Sciences; Novo Holdings; Paragon Biosciences, LLC; Valor Equity Partners; venBio Partners; and Vivo Capital.
In 2018, Harmony raised an additional $25 million in financing from Aisling Capital and Soros Fund Management to further support registration and commercial development of pitolisant.
Deal of the Year Award 2017
Harmony received Life Sciences Pennsylvania’s 2017 Deal of the Year award for the largest private equity investment in the biotech industry in Pennsylvania ($270 million in equity financing to acquire the exclusive U.S. rights to develop, register and market pitolisant from French company Bioprojet SCR). In 2018, Harmony raised an additional $25 million in financing to further support registration and commercial development of pitolisant.